13D Filing: Polaris Venture Partners VI, L.P. and Editas Medicine Inc (EDIT)

Page 11 of 14

Page 11 of 14 – SEC Filing


CUSIP No. 28106W103

SCHEDULE 13D

This Amendment No. 3
(Amendment No. 3) amends and supplements the Schedule 13D originally filed with the Securities and Exchange Commission (the SEC) on May 16, 2016 (the Schedule 13D), Amendment No. 1 to the Schedule
13D filed with the SEC on September 19, 2016 and Amendment No. 2 (Amendment No. 2) to the Schedule 13D filed with the SEC on May 22, 2017, by Polaris Venture Partners VI, L.P. (PVP VI), Polaris Venture
Founders Fund VI, L.P. (PVPFF VI), Polaris Venture Management Co. VI, L.L.C. (PVM VI), Jonathan A. Flint (Flint), Terrance G. McGuire (McGuire), Brian Chee (Chee), David Barrett
(Barrett), Amir Nashat (Nashat) and Bryce Youngren (Youngren and together with, PVP VI, PVPFF VI, PVM VI, Flint, McGuire, Chee, Barrett, and Nashat, collectively, the Reporting Persons), with respect
to shares of Common Stock of the Issuer beneficially owned by the Reporting Persons. This Amendment No. 3 is being filed to report the disposition of Common Stock by PVP VI and PVPFF VI on September 1, 2017, September 5, 2017,
September 7, 2017, September 8, 2017, September 11, 2017, September 12, 2017, September 13, 2017 and September 14, 2017; all other information is as set forth in the Schedule 13D, Amendment No. 1 and Amendment
No. 2. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms used herein but not defined shall have the meanings ascribed thereto in the Schedule 13D.

Item 4. Purpose of Transaction.

Item 4 of the Original
Schedule 13D is hereby amended to add the following statements:

On September 1, 2017, PVP VI sold 70,859 shares of Common Stock on the open market
and PVPFF VI sold 4,141 shares of Common Stock on the open market.

On September 5, 2017, PVP VI sold 141,412 shares of Common Stock on the open
market and PVPFF VI sold 8,264 shares of Common Stock on the open market.

On September 7, 2017, PVP VI sold 118,337 shares of Common Stock on the
open market and PVPFF VI sold 6,915 shares of Common Stock on the open market.

On September 8, 2017, PVP VI sold 142,986 shares of Common Stock on
the open market and PVPFF VI sold 8,356 shares of Common Stock on the open market.

On September 11, 2017, PVP VI sold 82,609 shares of Common Stock
on the open market and PVPFF VI sold 4,827 shares of Common Stock on the open market.

On September 12, 2017, PVP VI sold 13,778 shares of Common
Stock on the open market and PVPFF VI sold 805 shares of Common Stock on the open market.

On September 13, 2017, PVP VI sold 212,578 shares of
Common Stock on the open market and PVPFF VI sold 12,422 shares of Common Stock on the open market.

On September 14, 2017, PVP VI sold 162,231
shares of Common Stock on the open market and PVPFF VI sold 9,480 shares of Common Stock on the open market.

Item 5. Interest in Securities of the
Issuer.

Items 5(a) and (c) of the Schedule 13D are hereby amended and restated in their entirety as follows:

The information below is based on a total of 41,627,446 shares of Common Stock outstanding as reported on Form 10-Q,
Quarterly Report Pursuant to Section 13 or 15(d) of the Security Exchange Act of 1934 filed with the Securities and Exchange Commission by the Issuer on August 9, 2017.

(a) PVP VI directly beneficially owns 1,697,924 shares of Common Stock, or approximately 4.1% of the Common Stock outstanding. PVPFF VI directly beneficially owns 99,220 shares of Common Stock, or approximately 0.2% of the
Common Stock outstanding. PVM VI, as the general partner of PVP VI and PVPFF VI, may be deemed to indirectly beneficially own the securities owned by PVP VI and PVPFF VI. PVM VI, as general partner of PVP VI and PVPFF VI may be deemed to indirectly
beneficially own 1,797,144 shares of Common Stock, or approximately 4.3% of the Common Stock outstanding. Each of the Managing Members, in their respective capacities as managing members of PVM VI, may be deemed to indirectly beneficially own
1,797,144 shares of Common Stock, or approximately 4.3% of the Common Stock outstanding, aggregately owned by PVP VI and PVPFF VI.
(c) Except as described in this statement and this Item 5(c), none of the Reporting Persons has effected any transactions in the Common Stock in the 60 days prior to the date of this statement.

Follow Editas Medicine Inc.

Page 11 of 14